The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Opioid and Stimulant Coprescriptions among South Carolina Residents

Authors: Alexis Stoner, PhD, MPH, Lindsay Tjiattas-Saleski, DO, MBA, Emma Padgett, BS, MA, Cole Harp, DO, Martin Groke, DO, David Redden, PhD

Abstract

Objective: The South Carolina Department of Public Health (SCDPH) Prescription Drug Monitoring Program (PDMP) is used to monitor the prescribing patterns of controlled substances, including opioids and stimulants. Data collected by the National Center for Health Statistics show that the number of drug overdose deaths involving opioids and stimulants has been increasing since 1999. Although databases such as the PDMP monitor healthcare professionals' prescribing habits regarding opioids and stimulants individually, there has been little research regarding opioid-stimulant coprescribing patterns. Considering increasing death rates and the lack of research, data from the SCDPH PDMP were used to identify factors that influence opioid-stimulant coprescribing. It was hypothesized that younger age, higher daily morphine milligram milliequivalents (MMEs), increased duration of prescription, and male gender would be associated with increased opioid-stimulant coprescriptions.

Methods: Data were gathered from the SCDPH PDMP from 2016 to 2021. The variables assessed included patient age, patient sex, filling date, supply length, daily MMEs, and Lexicomp Drug Classification. A linear regression statistical analysis was then performed to analyze the data.

Results: Between January 1, 2016 and December 31, 2021, a total of 9,785,146 opioid prescriptions were filled by 2,158,564 individuals, with 161,103 (1.65%) of them receiving a concurrent stimulant prescription. Patients who were 50 years of age and younger had a 2.74 greater odds of receiving a concurrent stimulant prescription (P < 0.001), along with those who had an opioid prescription length of ? 30 days (odds ratio [OR] 4.38, P < 0.001). Being female (OR 1.58) and a daily MME ? 50 mg but ? 100 mg (OR 1.24) were both significantly found to indicate an increased odds of having a concurrent prescription.

Conclusions: This study indicates that those with longer opioid prescriptions, younger individuals, higher daily MMEs, and women are at an increased risk of opioid-stimulant coprescription. Future research should investigate other factors associated with opioid-stimulant coprescribing, such as education status, rurality, and whether specific opioid or stimulant agents are linked to coprescribing.

Full Article

Having trouble viewing the article content below? Click here to open it directly.

Images

Download Image

Download Image

Download Image

Download Image

References

1. Centers for Disease Control and Prevention David J. Sencer CDC Museum Public Health Academy. Uncovering the opioid epidemic. 2022. https://stacks.cdc.gov/view/cdc/129930. Accessed September 2025.
 
2. Centers for Disease Control and Prevention National Center for Health Statistics. U.S. overdose deaths decrease almost 27% in 2024. https://www.cdc.gov/nchs/pressroom/releases/20250514.html. Accessed September 2025.
 
3. Lundstrom E, Macmadu A, Steege A. Synthetic opioid and stimulant co-involved overdose deaths by occupation and industry-United States, 2022. MMWR Morb Mortal Wkly Rep 2025;75:173-178.
 
4. South Carolina Department of Health and Environmental Control. Controlled substance schedule. https://scdhec.gov/healthcare-quality/drug-control-register-verify/controlled-substance-schedule. Accessed March 29, 2023.
 
5. US Department of Justice, Drug Enforcement Administration. Controlled substance schedules. https://www.deadiversion.usdoj.gov/schedules/schedules.html. Accessed March 29, 2023.
 
6. Staley B, Robinson L, Claussen AH, et al. Attention-deficit/hyperactivity disorder diagnosis, treatment, and telehealth use in adults-National Center for Health Statistics Rapid Surveys System, United States, October-November 2023. MMWR Morb Mortal Wkly Rep 2024;73:890-895.
 
7. Donnelly S, Townsend C, Thomson L. 2024; Annual report South Carolina Prescription Monitoring Program. https://dph.sc.gov/sites/scdph/files/2025-06/2024_SC_PMP_Annual_Report.pdf. Accessed September 2025.
 
8. Centers for Disease Control and Prevention. Overdose prevention. U.S. opioid dispensing rate maps. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/opioid-dispensing-rate-maps.html. Accessed November 15, 2024.
 
9. Board A, Guy G, Jones C, et al. Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty-United States, 2014-2019. Drug Alcohol Depend 2020;217:108297.
 
10. Danielson M, Bohm M, et al. Trends in stimulant prescription fills among commercially insured children and adults-United States, 2016-2021. MMWR Morb Mortal Wkly Rep 2023;72:327-332.
 
11. Palis H, Xavier C, Dobrer S, et al. Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study. BMC Public Health 2022;22:2084.
 
12. Palis H, Gan W, Xavier C. Association of opioid and stimulant use disorder diagnoses with fatal and nonfatal overdose among people with a history of incarceration. JAMA Netw Open 2022;5:e2243653.
 
13. Han B, Jones CM, Compton WM. Trends and characteristics of concurrent stimulant and opioid use disorders in the United States. Front Psychiatry 2022;13:918197.
 
14. Song W, Lee S, Bates D, et al. Opioid and stimulant co-prescribing: our efforts and remaining open questions-authors reply. Lancet Reg Health Am 2025;45:101118.
 
15. Lee S, Song W, Bates D, et al. The recent trend of twin epidemic in the United States: a 10-year longitudinal cohort study of co-prescriptions of opioids and stimulants. Lancet Reg Health Am 2025;44:101030.
 
16. Campbell CI, Weisner C, LeResche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010;100:2541-2547.
 
17. Centers for Medicare & Medicaid Services. Stimulant and related medications: use in adults. https://www.cms.gov/sites/default/files/repo-new/68/stim%20adult%20FS%20102915.pdf. Accessed September 2025.
 
18. Vos M, Hartman CA. The decreasing prevalence of ADHD across the adult lifespan confirmed. J Glob Health 2022;12:03024.
 
19. Corey PJ, Heck M, Weathermon RA. Amphetamines to counteract opioid-induced sedation. Ann Pharmacother 1999;33:1362-1366.
 
20. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003;4:135-140.
 
21. Dalal S, Melzack R. Potentiation of opioid analgesia by psychostimulant drugs. J Pain Symptom Manage 1998;16:245-253.
 
22. Farzam K, Faizy RM, Saadabadi A. Stimulants. StatPearls. NCBI Bookshelf version. StatPearls Publishing;2023. https://www.ncbi.nlm.nih.gov/books/NBK539896. Accessed September 2025.
 
23. Stokes A, Lundberg DJ, Sheridan B, et al. Association of obesity with prescription opioids for painful conditions in patients seeking primary care in the US. JAMA Netw Open 2020;3:e202012.
 
24. Hurley RW, Adams MCB. Sex, gender, and pain: an overview of a complex field. Anesth Analg 2008;107:309-317.
 
25. Kim ML, Dalvi N, Valerio DD, et al. Prescribed stimulant medications: trends in the last decade, pre and post COVID-19 response. Explor Res Clin Soc Pharm 2023;11:100314.
 
26. Rikin S, Perez HR, Zhang C, et al. Changes in outpatient opioid prescribing during the COVID-19 pandemic: an interrupted time series analysis. J Prim Care Community Health 2022;13:21501319221076926.